At this price the dividend yeld is 3.50%: it is a proxy of high grade bond and we think that the split between the core human pharma and the rest of the Group probably could come in late 2016.
Strong financial position.
Strong financial position.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.